Adamas Pharmaceuticals Inc (ADMS) [Rocket]

Overview

Adamas Pharmaceuticals Inc (ADMS)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
02/14/2022	SC 13G/A	ARMISTICE CAPITAL, LLC reports a 0% stake in Adamas Pharmaceuticals, Inc.
02/11/2022	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/26/2022	SC 13G/A	Opaleye Management Inc. reports a 0% stake in Adamas Pharmaceuticals, Inc.
12/10/2021	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/06/2021	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]:
12/02/2021	EFFECT	Form EFFECT - Notice of Effectiveness:
11/24/2021	4	BIGHAM MICHAEL (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-20	Dec-31-19	Dec-31-18	Dec-05-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	74.5	54.6	34.0	73.3	0.6	0.6	1.9	55.8
Revenue growth	36.3%	60.5%	5862.5%		-0.2%	-70.1%	-96.6%	-21.4%
Cost of goods sold	2.0	2.5	0.6	0.6	0.0	0.0	0.0	0.0
Gross profit	72.4	52.2	33.4	72.7	0.6	0.6	1.9	55.8
Gross margin	97.3%	95.5%	98.1%	99.1%	97.0%	100.0%	100.0%	100.0%
Selling, general and administrative	106.8	114.4	109.1	148.4	61.3	30.3	23.5
Research and development	9.7	30.0	39.3		27.2	31.2	35.9	21.9
General and administrative								15.5
EBIT	-44.2	-92.2	-115.0	-115.0	-87.9	-61.0	-57.4	18.5
EBIT margin	-59.3%	-168.8%	-337.8%	-156.8%	-15398.6%	-10661.5%	-2997.8%	33.2%
Pre-tax income	-57.4	-105.2	-131.0	-131.0	-91.2	-60.2	-57.1	17.6
Income taxes	0.0	0.0	0.0	0.0	-1.7	-0.1	-5.3	7.4
Tax rate	0.0%	0.0%	0.0%	0.0%	1.9%	0.2%	9.2%	41.9%
Net income	-57.4	-105.2	-131.0	-131.0	-89.5	-60.1	-51.8	9.0
Net margin	-77.1%	-192.5%	-384.8%	-178.6%	-15672.5%	-10499.7%	-2703.7%	16.1%

Diluted EPS	($2.03)	($3.80)	($4.87)	($4.87)	($3.97)	($2.77)	($2.86)	$0.52
Shares outstanding (diluted)	28.3	27.7	26.9	26.9	22.6	21.7	18.1	17.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.